According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- troriluzole’s regulatory prospects as a treatment for spinocerebellar ataxia (“SCA”), and/or the sufficiency of data that Biohaven submitted in support of troriluzole’s regulatory approval for this indication, were overstated;
- BHV-7000’s efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated;
- all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven’s business and financial condition; and
- as a result, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
